Longeveron (LGVN) Reports Q4 Loss of $0.20/sh
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Needham Starts NeoVolta (NEOV) at Buy
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
Longeveron Announces Fourth Quarter and Full Year 2021 Financial Results and Operational Progress
March 11, 2022 8:00 AM ESTCurrently Enrolling Clinical Trials with Lomecel-B in Three Disease Indications: Hypoplastic Left Heart Syndrome (Phase 2a), Alzheimers Disease (Phase 2a), and Covid-related Acute Respiratory Distress Syndrome (Phase 1)
Lomecel-B for HLHS Granted Rare Pediatric Disease and Orphan Drug Designation by the US FDA
Japanese Phase 2 Aging Frailty Trial Expected to Initiate in First Half of 2022
Multiple Clinical Data Publications Expected in 2022
- Conference Call Today at 8:30 a.m. EST -
MIAMI, March 11, 2022 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ:... More
